Melanoma Research Victoria

Source: MDLinx, April 2019 Authors evaluated the survival outcomes in candidates who underwent retreatment of recurrent cutaneous melanoma of the head and neck between January 1, 2000, and December 31, 2015. Development of recurrence was observed in 33 cases. At last follow-up, they found 66% of candidates who developed local recurrence first and 50% of […]

Read the full story

Source: MDLinx, April 2019 In this single-arm pilot study in a swine animal model, authors estimated the accessibility of contrast-enhanced ultrasound (CEUS) to recognize the sentinel lymph node (SLN) associated with cutaneous melanoma. They observed 5 primary cutaneous melanomas with a mean area of 4.36?±?4.75?cm2 and Breslow depth of 3.6?±?1.5?mm. They also recognized 6 SLN with […]

Read the full story

JCI insight MicroRNA-155 coordinates the immunological landscape within murine melanoma and correlates with immunity in human cancers H. Atakan Ekiz, Thomas B. Huffaker, Allie H. Grossmann, W. Zac Stephens, Matthew A. Williams, June L. Round, and Ryan M. O’Connell First published February 5, 2019 Journal of Biological Cancer WNT1-inducible signaling pathway protein 1 (WISP1/CCN4) stimulates […]

Read the full story

Source: Pharmaceutical Business Review, March 2019 Merck has secured approval from the US Food and Drug Administration (FDA) for its Keytruda (pembrolizumab) as the adjuvant treatment for patients with melanoma with involvement of lymph node(s) following complete resection. The recommended dose of Keytruda for the adjuvant treatment of adult patients with melanoma is 200 mg […]

Read the full story